favezelimab/pembrolizumab

MK-4280A is Merck's fixed-dose coformulation of favezelimab, an experimental antibody against LAG-3, with pembrolizumab (Keytruda), the anti-PD-1 antibody that generated roughly $30B in 2024 sales and anchors Merck's oncology franchise [1]. The program is Merck's structural answer to Bristol Myers Squibb's Opdualag (nivolumab plus relatlimab), which validated dual PD-1/LAG-3 blockade in first-line melanoma. Multiple Phase 2 readouts in relapsed/refractory Hodgkin lymphoma, endometrial cancer, and cutaneous squamous cell carcinoma will determine whether the coformulation can extend the Keytruda franchise ahead of biosimilar competition beginning in 2028 [2]. A prior Phase 3 in microsatellite-stable (MSS) colorectal cancer (KEYFORM-007) was terminated for futility in 2023 and is no longer part of the active program [4].

Favezelimab has never been approved anywhere. Pembrolizumab is approved across more than two dozen indications, but the fixed-dose coformulation MK-4280A remains investigational for every disease under study. Public disclosures do not indicate breakthrough therapy, fast track, or orphan designations for the coformulation. The lead Phase 2 readout is MK-4280A-008 (NCT05508867), a randomized trial of the coformulation versus physician's choice chemotherapy in PD-(L)1-refractory classical Hodgkin lymphoma, which enrolled 203 patients and has completed treatment with progression-free survival as the primary endpoint [3]. At 203 patients this is a hypothesis-testing Phase 2, not a registrational Phase 3, though a strongly positive result could support accelerated approval in a small orphan-like population. Endometrial and cSCC studies remain earlier stage. The Phase 3 in second- and third-line MSS colorectal cancer (KEYFORM-007) was stopped for futility in 2023, removing the largest addressable population from the program and forcing a strategic narrowing to indications where a LAG-3 signal is more plausible [4]. The next commercially meaningful catalysts are the Hodgkin lymphoma progression-free survival data (expected at ASH December 2026 or ASCO June 2027) and any move to register the coformulation as a Keytruda line-extension asset before 2028 loss of exclusivity.

T cells carry inhibitory receptors that act like brakes, preventing the immune system from attacking normal tissue. Tumors exploit those brakes to avoid destruction. PD-1 is the best-known brake, and blocking it with pembrolizumab unleashes T cells against many cancers. LAG-3 (lymphocyte activation gene 3) is a second brake on the same T cells [5]. It engages MHC class II on antigen-presenting cells and, more recently identified, FGL1 secreted by hepatocytes and some tumors, both of which dampen T-cell activity [5]. The bet behind dual PD-1/LAG-3 blockade is that exhausted T cells inside tumors express both receptors, and releasing only one brake leaves the other engaged. Classical Hodgkin lymphoma is a biologically defensible test bed: the malignant Reed-Sternberg cells sit in an inflamed microenvironment rich in exhausted T cells that co-express PD-1 and LAG-3, and MHC class II (a LAG-3 ligand) is characteristically retained or upregulated on the tumor cells themselves, unlike many solid tumors that downregulate it. Genetic validation of LAG-3 is modest: knockout mice show enhanced anti-tumor immunity but not the dramatic phenotypes seen with PD-1 loss. Clinical validation is now uneven and trending negative in unselected populations. Opdualag doubled progression-free survival over nivolumab alone in first-line melanoma (RELATIVITY-047), earning FDA approval in 2022. But in May 2026 Regeneron's Phase 3 of fianlimab plus cemiplimab versus pembrolizumab monotherapy in 1,546 first-line melanoma patients failed to reach statistical significance for PFS despite a 5.1-month numerical median advantage (11.5 vs 6.4 months) [8]. That is the only head-to-head test of a LAG-3 combination against pembrolizumab monotherapy, and it did not clear the bar. Combined with Merck's own KEYFORM-007 futility stop in MSS CRC, the mechanistic case has narrowed: LAG-3 blockade appears to add value only in indications with a pre-specified biological rationale, not as a universal amplifier of PD-1 blockade. No validated LAG-3 predictive biomarker has emerged. The coformulation itself is a commercial/convenience construct - no public data show a PK/PD advantage over co-administration.

The most mature readout is MK-4280A-008 (NCT05508867), a randomized open-label Phase 2 in patients with classical Hodgkin lymphoma whose disease progressed on prior PD-(L)1 therapy [3]. Enrollment closed at 203 patients, randomized to coformulated favezelimab/pembrolizumab or investigator's choice of bendamustine, gemcitabine, or single-agent chemotherapy. The primary endpoint is investigator-assessed progression-free survival by Lugano criteria (the standard scan-based response assessment for lymphoma). Key secondary endpoints are overall response rate and duration of response. This is a reasonable design for a difficult population: PD-1-refractory Hodgkin lymphoma has few standard options, physician's choice is a defensible comparator, and PFS in a chemo-comparator trial should read out cleanly. The concerns are that 203 patients is a hypothesis-testing Phase 2 rather than a fully powered registrational trial, the control arm is heterogeneous, and Hodgkin lymphoma is a small commercial market. The colorectal Phase 3 (KEYFORM-007) is the more instructive design lesson: enrolling unselected MSS (microsatellite-stable) CRC patients - a population where PD-1 monotherapy is known to be inactive because tumors carry few neoantigens, unlike MSI-H (microsatellite-instability-high) tumors where Keytruda is standard of care - for a mechanism with no biomarker was aggressive, and the futility stop in 2023 validated that skepticism. Endometrial and cSCC studies are earlier and use standard immunotherapy endpoints (ORR, PFS) with pembrolizumab-based comparators or historical controls.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, heavier-than-usual blinding, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk dominates. The MSS colorectal failure is not a data point that can be waved away: it was a large, well-run Phase 3 in a mechanism-plausible population, and it failed. The May 2026 fianlimab Phase 3 miss is a second, external negative signal in the LAG-3 class - a 1,546-patient trial that failed to beat pembrolizumab monotherapy in first-line melanoma despite the RELATIVITY-047 precedent for the mechanism [8]. Two Phase 3 misses in the class in three years narrow the plausible label to indications with a specific biological rationale (like Hodgkin lymphoma's MHC-class-II-rich microenvironment) rather than a broad PD-1 amplifier story. If the MK-4280A-008 Hodgkin lymphoma PFS misses or lands with a hazard ratio above 0.8, the program's rationale narrows to endometrial and cSCC, both smaller markets with active pembrolizumab-monotherapy competition. Safety risk is moderate. Dual checkpoint blockade increases immune-related adverse events (colitis, hepatitis, endocrinopathies) versus PD-1 alone, though the Opdualag experience suggests LAG-3 adds less toxicity than CTLA-4 does [7]. Coformulation itself introduces CMC (Chemistry, Manufacturing, and Controls - the regulatory validation of how a drug is made) risk that a co-administered regimen would not carry, and there is no published PK/PD justification for the fixed-dose format over co-administration. Commercial risk is structural: relapsed/refractory classical Hodgkin lymphoma is roughly 1,500-2,000 new US cases per year, implying a peak-sales ceiling on the order of $200-400M even with strong uptake - trivial next to Keytruda's ~$29.5B 2024 base [1]. The strategic point of the program is franchise defense ahead of 2028 biosimilar entry, not standalone revenue. Payers will demand meaningful benefit over pembrolizumab monotherapy, not just numeric superiority, before covering a premium-priced coformulation.

Worth watching, with a specific catalyst. The MK-4280A-008 Hodgkin lymphoma readout - expected at ASH December 2026 or ASCO June 2027 - is the near-term signal that matters: a clean PFS win over physician's choice chemotherapy in PD-1-refractory patients would be the first positive Phase 2/3 evidence for the coformulation and would revive interest in LAG-3 as a franchise-extension mechanism for Merck. A miss or a borderline hazard ratio compounds KEYFORM-007 and the fianlimab Phase 3 failure and effectively closes the program's path to a broad label. For Merck's stock, this asset is a small piece of the 2028 loss-of-exclusivity puzzle - peak sales in Hodgkin lymphoma alone are two orders of magnitude below Keytruda's current run rate - not the main mitigant (subcutaneous pembrolizumab and the anti-TROP2 antibody-drug conjugate portfolio matter more), but it is a useful tell on whether Merck's late-stage immuno-oncology bench can deliver anything beyond Keytruda itself [2].